Stockholders' Equity (Tables)
|
3 Months Ended |
Mar. 31, 2020 |
|---|
| Stockholders' Equity Note [Abstract] |
|
| Preferred Stock Conversion calculation, Series H |
| Number
of Series H Preferred Stock outstanding |
|
|
8 |
|
| Multiplied
by the stated value |
|
$ |
154 |
|
| Equals
the gross stated value |
|
$ |
1,232 |
|
| Divided
by the conversion price |
|
$ |
36.96 |
|
| Equals
the convertible shares of common stock |
|
|
33 |
|
| Multiplied
by the fair market value of common stock at March 31, 2020 |
|
$ |
0.45 |
|
| Equals
the payment |
|
$ |
15 |
|
|
| Preferred Stock Conversion calculation, Series H-3 |
| Number
of Series H-3 Preferred Stock outstanding |
|
|
2,189 |
|
| Multiplied
by the stated value |
|
$ |
138 |
|
| Equals
the gross stated value |
|
$ |
302,082 |
|
| Divided
by the conversion price |
|
$ |
33.12 |
|
| Equals
the convertible shares of common stock |
|
|
9,121 |
|
| Multiplied
by the fair market value of common stock at March 31, 2020 |
|
$ |
0.45 |
|
| Equals
the payment |
|
$ |
4,104 |
|
|
| Preferred Stock Conversion calculation, Series H-4 |
| Number
of Series H-4 Preferred Stock outstanding |
|
|
5,028 |
|
| Multiplied
by the stated value |
|
$ |
235.50 |
|
| Equals
the gross stated value |
|
$ |
1,184,094 |
|
| Divided
by the conversion price |
|
$ |
2.826 |
|
| Equals
the convertible shares of common stock |
|
|
419,000 |
|
| Multiplied
by the fair market value of common stock at March 31, 2020 |
|
$ |
0.45 |
|
| Equals
the payment |
|
$ |
188,550 |
|
|
| Preferred Stock Conversion calculation, Series H-6 |
| Number
of Series H-6 Preferred Stock outstanding |
|
|
29,822 |
|
| Multiplied
by the stated value |
|
$ |
72.00 |
|
| Equals
the gross stated value |
|
$ |
2,147,184 |
|
| Divided
by the conversion price |
|
$ |
0.72 |
|
| Equals
the convertible shares of common stock |
|
|
2,982,200 |
|
| Multiplied
by the fair market value of common stock at March 31, 2020 |
|
$ |
0.45 |
|
| Equals
the payment |
|
$ |
1,341,990 |
|
|
| Schedule of share-based compensation, stock options, activity |
| |
|
Shares
Underlying Options |
|
|
Weighted
Average Exercise Price |
|
|
Weighted
Average Remaining Contractual Life (years) |
|
|
Aggregate
Intrinsic Value |
|
| Outstanding
at December 31, 2019 |
|
|
380,396 |
|
|
$ |
14.43 |
|
|
|
6.84 |
|
|
|
- |
|
| Expired |
|
|
(73,194 |
) |
|
|
35.53 |
|
|
|
- |
|
|
|
|
|
| Outstanding
at March 31, 2020 |
|
|
307,202 |
|
|
$ |
9.39 |
|
|
|
8.20 |
|
|
|
- |
|
|
| Schedule of share-based compensation |
| |
|
Three
Months ended March 31, |
|
| |
|
2020 |
|
|
2019 |
|
| Research
and development |
|
|
3,758 |
|
|
|
3,717 |
|
| Selling,
general and administrative |
|
|
45,586 |
|
|
|
484,240 |
|
| Total
$ |
|
|
49,344 |
|
|
$ |
487,957 |
|
|
| Schedule of common stock warrant activity |
| |
|
Shares
Underlying Warrants |
|
|
Weighted
Average Exercise Price |
|
|
Weighted
Average Remaining Contractual Life (years) |
|
|
Aggregate
Intrinsic Value |
|
| Outstanding
at December 31, 2019 |
|
|
4,300,560 |
|
|
$ |
1.77 |
|
|
|
5.06 |
|
|
|
- |
|
| Granted |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Exercised/Forfeited |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Outstanding
at March 31, 2020 |
|
|
4,300,560 |
|
|
$ |
1.77 |
|
|
|
4.81 |
|
|
|
- |
|
|